Home › Funds › Palo Alto Investors LP › TRAX
Palo Alto Investors LP position in TRAX
FIRST TRACKS BIOTHERAPEUTICS · Health Care
Palo Alto Investors LP reported holding 741,097 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$26.3M, representing 3.91% of its reported portfolio and ranking #12 among its reported holdings. Palo Alto Investors LP has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's TRAX position evolved
Palo Alto Investors LP first disclosed a stake in TRAX in Q2 2026 at 603,489 shares (US$12.1M). The position peaked in Q3 2026 at 741,097 shares, worth US$26.3M. Across 2 filings, Palo Alto Investors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 741,097 shares valued at US$26.3M — an increase of 137,608 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 603.49K | $12.14M | New |
| Q3 2026 | 741.10K | $26.26M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRAX and 13F data
TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 174 other funds we track also report a position in TRAX — the largest reported positions include EcoR1 Capital, LLC (US$112.5M), TCG Crossover Management, LLC (US$102.6M), Affinity Asset Advisors, LLC (US$73.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRAX
- EcoR1 Capital, LLC 3.17M sh · $112.50M · Q3 2026
- TCG Crossover Management, LLC 2.90M sh · $102.61M · Q3 2026
- Affinity Asset Advisors, LLC 2.08M sh · $73.72M · Q3 2026
- Sanofi 821.92K sh · $29.13M · Q3 2026
- Trails Edge Capital Partners, LP 814.00K sh · $28.85M · Q3 2026
- STEMPOINT CAPITAL LP 649.92K sh · $23.03M · Q3 2026
- 683 Capital Management, LLC 600.00K sh · $21.26M · Q3 2026
- Sofinnova Investments, Inc. 383.59K sh · $13.59M · Q3 2026
- MPM BioImpact LLC 254.37K sh · $9.02M · Q3 2026
- Boxer Capital Management, LLC 240.00K sh · $8.51M · Q3 2026
- Vestal Point Capital, LP 169.74K sh · $6.02M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 160.24K sh · $5.68M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held TRAX?
Palo Alto Investors LP has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Palo Alto Investors LP's current position in TRAX?
As of Q3 2026, Palo Alto Investors LP holds 741.10K shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $26.26M, representing 3.91% of its reported portfolio and ranking #12.
Has Palo Alto Investors LP been buying or selling TRAX?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP increased its position in TRAX. The position peaked in Q3 2026 at 741.10K shares.
Which other funds hold TRAX?
Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, among 174 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.